drugset / Trial / NCT06454669

Dronabinol as an Adjunct for Reducing Pain

NCT06454669

Phase 2 Recruiting 75 enrolled Christopher D. Verrico
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.

Timeline

Start
2024-06-15
Primary completion
2028-12-31
Completion
2029-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dronabinol Other / unclassified 15 mg Oral

Indications